Product
DP303c
3 clinical trials
3 indications
Indication
Breast Cancer (HER2-positive)Indication
HER2-positive Advanced Breast CancerIndication
HER2-positive Advanced Solid TumorsClinical trial
A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303c Versus Trastuzumab Emtansine in Patients With HER2-positive Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303cversus Trastuzumab Combined With Vinorelbine/Capecitabine in of HER2-positive Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-12-23